129 related articles for article (PubMed ID: 9655287)
1. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma.
Ribeiro U; Finkelstein SD; Safatle-Ribeiro AV; Landreneau RJ; Clarke MR; Bakker A; Swalsky PA; Gooding WE; Posner MC
Cancer; 1998 Jul; 83(1):7-18. PubMed ID: 9655287
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
[TBL] [Abstract][Full Text] [Related]
4. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
5. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Gibson MK; Abraham SC; Wu TT; Burtness B; Heitmiller RF; Heath E; Forastiere A
Clin Cancer Res; 2003 Dec; 9(17):6461-8. PubMed ID: 14695149
[TBL] [Abstract][Full Text] [Related]
7. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
10. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
[TBL] [Abstract][Full Text] [Related]
11. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
14. Relationship of p53 Genotype to Second-look Recurrence and Survival in Ovarian Epithelial Malignancy.
Kanbour-shakir A; Kounelis S; Papadaki H; Raptis S; Edwards RP; Kelley JL; Price FV; Bakker A; Swalsky PA; Przygodzki RM; Finkelstein SD
Mol Diagn; 1996 Jun; 1(2):121-129. PubMed ID: 10330207
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history.
Bennett WP; von Brevern MC; Zhu SM; Bartsch H; Muehlbauer KR; Hollstein MC
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):963-6. PubMed ID: 9367071
[TBL] [Abstract][Full Text] [Related]
17. Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus.
Safatle-Ribeiro AV; Ribeiro U; Sakai P; Clarke MR; Fylyk SN; Ishioka S; Gama-Rodrigues J; Finkelstein SD; Reynolds JC
Cancer Detect Prev; 2000; 24(1):13-23. PubMed ID: 10757119
[TBL] [Abstract][Full Text] [Related]
18. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in esophageal cancer following induction chemoradiotherapy.
Shears LL; Ribeiro U; Kane J; Safatle-Ribeiro A; Watkins S; Posner M
J Surg Res; 1998 Sep; 79(1):20-4. PubMed ID: 9735235
[TBL] [Abstract][Full Text] [Related]
20. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]